Latest Conference Articles

Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis

Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis

October 22nd 2025

The Menopause Society Annual Meeting

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

Black Women Prescribed Menopausal Hormone Therapy at Significantly Lower Rates Despite More Severe Symptoms, Study Finds

Black Women Prescribed Menopausal Hormone Therapy at Significantly Lower Rates Despite More Severe Symptoms, Study Finds

October 22nd 2025

The Menopause Society Annual Meeting

TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.

Age, Not Menopause Stage, Drives Cortical Volume Reduction in Midlife Women, New Study Suggests

Age, Not Menopause Stage, Drives Cortical Volume Reduction in Midlife Women, New Study Suggests

October 22nd 2025

The Menopause Society Annual Meeting

TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.

New Large-Scale Study Challenges Previous Research on Menopause and Brain Structure

New Large-Scale Study Challenges Previous Research on Menopause and Brain Structure

October 21st 2025

The Menopause Society Annual Meeting

New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.

Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks

Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks

October 21st 2025

The Menopause Society Annual Meeting

Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.

Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause

Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause

October 21st 2025

The Menopause Society Annual Meeting

TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.

6 Latent Menopausal Phenotypes Identified by Machine Learning in 10-Year SWAN Follow-Up

6 Latent Menopausal Phenotypes Identified by Machine Learning in 10-Year SWAN Follow-Up

October 21st 2025

The Menopause Society Annual Meeting

TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.

The Only Predictable Thing About Perimenopause Is Unpredictability, Says Dr Marla Shapiro

The Only Predictable Thing About Perimenopause Is Unpredictability, Says Dr Marla Shapiro

October 21st 2025

The Menopause Society Annual Meeting

TMS 2025. University of Toronto professor Dr Marla Shapiro explains why perimenopause is unpredictable, including age of onset, duration, and symptoms.

Diagnosing DVT: Clinical Pearls for Challenging Presentations

Diagnosing DVT: Clinical Pearls for Challenging Presentations

October 17th 2025

FMX

A family medicine physician shares a case of massive PE presenting as syncope and explains the history questions that prevent missed DVT diagnoses in primary care.

Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD

Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD

October 17th 2025

FMX

Primary care physicians enhance early detection and management of vascular diseases, emphasizing patient history, screening, and strong relationships for better outcomes.